{
    "clinical_study": {
        "@rank": "6577", 
        "arm_group": [
            {
                "arm_group_label": "TD-1607 or placebo (Dose1)", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }, 
            {
                "arm_group_label": "TD-1607 or placebo (Dose 2)", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }, 
            {
                "arm_group_label": "TD-1607 or placebo (Dose 3)", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }, 
            {
                "arm_group_label": "TD-1607 or placebo (Dose 4)", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }, 
            {
                "arm_group_label": "TD-1607 or placebo (Dose 5) [Optional]", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }, 
            {
                "arm_group_label": "TD-1607 or placebo (Dose 6) [Optional]", 
                "arm_group_type": "Experimental", 
                "description": "TD-1607 or placebo administered intravenously"
            }
        ], 
        "brief_summary": {
            "textblock": "TD-1607, administered intravenously as multiple ascending doses, will be investigated in\n      healthy subjects to assess its tolerability, safety, and pharmacokinetics."
        }, 
        "brief_title": "TD-1607 MAD Study in Healthy Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Infections", 
            "Bacterial Infections"
        ], 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a healthy nonsmoking male or a female (of non-childbearing potential) and\n             18 to 55 years old, inclusive, at Screening.\n\n          -  Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least\n             50 kg.\n\n        Subject has no clinically significant abnormalities in the results of laboratory\n        evaluations at Screening and Day -1.\n\n        Exclusion Criteria:\n\n          -  Subject has evidence or history of clinically significant, relevant hematological,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,\n             neurological, or allergic disease (except for untreated, asymptomatic seasonal\n             allergies at time of dosing).\n\n          -  Subject has a history of allergies or hypersensitivities to glycopeptide (e.g.,\n             vancomycin) or beta-lactam (e.g., penicillin or cephalosporin) antibiotics.\n\n          -  Subject has participated in another clinical trial of an investigational drug (or\n             medical device) within 60 days (or 5 half-lives, whichever is longer) prior to\n             Screening or is currently participating in another trial of an investigational drug\n             (or medical device).\n\n          -  Subject has previously participated in a trial for TD-1607."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949103", 
            "org_study_id": "0104"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TD-1607 or placebo (Dose1)", 
                    "TD-1607 or placebo (Dose 2)", 
                    "TD-1607 or placebo (Dose 3)", 
                    "TD-1607 or placebo (Dose 4)", 
                    "TD-1607 or placebo (Dose 5) [Optional]", 
                    "TD-1607 or placebo (Dose 6) [Optional]"
                ], 
                "intervention_name": "TD-1607", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "TD-1607 or placebo (Dose1)", 
                    "TD-1607 or placebo (Dose 2)", 
                    "TD-1607 or placebo (Dose 3)", 
                    "TD-1607 or placebo (Dose 4)", 
                    "TD-1607 or placebo (Dose 5) [Optional]", 
                    "TD-1607 or placebo (Dose 6) [Optional]"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Gram-positive", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "PPD, Phase 1 Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Double\u2212Blind, Placebo\u2212Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD\u22121607, a Glycopeptide\u2212Cephalosporin Heterodimer Antibiotic, in Healthy Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events", 
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "17 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949103"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetics", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "AUC0-24", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "AUCinf", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "CL", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Vdss", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Amount excreted in urine (Ae", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Fraction eliminated in urine (fe)", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "CLr", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }, 
            {
                "description": "Pharmacokinetics", 
                "measure": "Ctrough", 
                "safety_issue": "No", 
                "time_frame": "17 Days"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}